

## Appendix 2. Estimated Background Prevalence and Timing of Onset For Obstetric Safety Outcomes

Safety Outcomes	ICD-9 Codes	Background Prevalence (per 1,000 births)	Expected Onset During Pregnancy
Hyperemesis	643.x	3-20 <sup>1</sup>	5-20 weeks
Chronic hypertension	642.0	30-50 <sup>2</sup>	<20 weeks
Mild preeclampsia	642.4	25-35 <sup>3*</sup>	≥20 weeks
Severe preeclampsia or eclampsia	642.5-642.7		≥20 weeks
Gestational hypertension	642.3, 642.9	25-30 <sup>3</sup>	≥20 weeks
Gestational diabetes	648.8	35-72 <sup>4</sup>	≥24 weeks
Proteinuria	646.2	20 <sup>5</sup>	Throughout pregnancy
Urinary tract infection	599.0	20-30 <sup>6</sup>	Throughout pregnancy
Chorioamnionitis	648.8	20-40 <sup>7</sup>	Delivery date or early postpartum
Puerperal infection	670.x	10-80 <sup>8,9</sup>	Delivery date or up to 10 days postpartum
Venous complications of pregnancy	671.3-.5	0.5-1.0 <sup>10</sup>	Late pregnancy or postpartum
Pulmonary embolus	673.2-.3	0.2-0.5 <sup>10,11</sup>	Late pregnancy or postpartum
Peripartum cardiomyopathy	599.0	0.3 <sup>12</sup>	Late pregnancy or postpartum

ICD-9, *International Classifications of Diseases, Ninth Revision*

\*This rate is for preeclampsia or eclampsia. Background rates specific for how preeclampsia and eclampsia were classified in this study were not available.

Kharbanda EO, Vazquez-Benitez G, Lipkind H, Naleway A, Lee G, Nordin JD, for the Vaccine Safety Datalink Team. Inactivated influenza vaccine during pregnancy and risks for adverse obstetric events. *Obstet Gynecol* 2013;122.

The authors provided this information as a supplement to their article.

## Appendix References

1. Goodwin TM. Hyperemesis gravidarum. *Obstetrics and gynecology clinics of North America*. Sep 2008;35(3):401-417, viii.
2. ACOG Practice Bulletin No. 125: Chronic hypertension in pregnancy. *Obstet Gynecol*. Feb 2012;119(2 Pt 1):396-407.
3. Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. *Am J Hypertens*. May 2008;21(5):521-526.
4. Bardenheier BH, Elixhauser A, Imperatore G, et al. Variation in prevalence of gestational diabetes mellitus among hospital discharges for obstetric delivery across 23 States in the United States. *Diabetes Care*. May 2013;36(5):1209-1214.
5. Podymow T, August P, Akbari A. Management of renal disease in pregnancy. *Obstetrics and gynecology clinics of North America*. Jun 2010;37(2):195-210.
6. Mazor-Dray E, Levy A, Schlaeffer F, Sheiner E. Maternal urinary tract infection: is it independently associated with adverse pregnancy outcome? *J Matern Fetal Neonatal Med*. Feb 2009;22(2):124-128.
7. Martinelli P, Sarno L, Maruotti GM, Paludetto R. Chorioamnionitis and prematurity: a critical review. *J Matern Fetal Neonatal Med*. Oct 2012;25 Suppl 4:29-31.
8. Maharaj D. Puerperal Pyrexia: a review. Part II. *Obstetrical & gynecological survey*. Jun 2007;62(6):400-406.
9. Maharaj D. Puerperal pyrexia: a review. Part I. *Obstetrical & gynecological survey*. Jun 2007;62(6):393-399.
10. Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. *N Engl J Med*. Nov 6 2008;359(19):2025-2033.
11. Morris JM, Algert CS, Roberts CL. Incidence and risk factors for pulmonary embolism in the postpartum period. *Journal of thrombosis and haemostasis : JTH*. May 2010;8(5):998-1003.
12. Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. *JAMA*. Mar 1 2000;283(9):1183-1188.

Kharbanda EO, Vazquez-Benitez G, Lipkind H, Naleway A, Lee G, Nordin JD, for the Vaccine Safety Datalink Team. Inactivated influenza vaccine during pregnancy and risks for adverse obstetric events. *Obstet Gynecol* 2013;122.

The authors provided this information as a supplement to their article.